Showing posts with label FUNCTION. Show all posts
Showing posts with label FUNCTION. Show all posts

Tuesday, August 22, 2017

FISH OIL SUPPLEMENTS MAY IMPROVE MEMORY FUNCTION



Rhode Island Hospital researchers have completed a study that found regular use of fish oil supplements (FOS) was associated with a significant reduction in cognitive decline and brain atrophy in older adults. The study examined the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative (ADNI) and indicators of cognitive decline. The findings are published online in advance of print in the journal Alzheimer's & Dementia

At least one person is diagnosed every minute with Alzheimer's disease (AD) and despite best efforts, we have not yet found a cure for this pervasive and debilitating disease," said principal investigator Lori Daiello, PharmD, of the Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital. "The field is currently engaged in numerous studies to find better treatments for people suffering with AD; however, researching ways to prevent AD or slow cognitive decline in normal aging is of utmost importance."

In this retrospective study, older adults involved in the ADNI study were assessed with neuropsychological tests and brain magnetic resonance imaging (MRI) every six months. The group included 229 older adults who were cognitively normal; 397 who were diagnosed with mild cognitive impairment; and 193 with AD.

The study found that fish oil supplement use during the study was associated with significantly lower rates of cognitive decline as measured by the Alzheimer's Disease Assessment Scale (ADAS-cog), and the Mini Mental State Exam (MMSE), but this benefit was observed only for the group of participants without dementia at the time of enrollment.

"Additionally, serial brain imaging conducted during this study showed that the participants with normal cognition who reported taking fish oil supplements demonstrated less brain shrinkage in key neurological areas, compared to those who did not use the supplements," Daiello said. "Also, the positive findings on cognitive testing and brain MRI were only observed in persons who did not carry the best-studied genetic risk factor for AD, APOE-4. More research is needed, but these findings are promising and highlight the need for future studies to expand the current knowledge of the effects of FOS use on cognitive aging and AD."

It is estimated that more than 5 million people in the U.S. have Alzheimer's disease. It is the most common form of dementia and is the sixth leading cause of death in the U.S.




Friday, July 28, 2017

ANTI EPILEPSY DRUG PRESERVES BRAIN FUNCTION AFTER STROKE


New research suggests that an already-approved drug could dramatically reduce the debilitating impact of strokes, which affect nearly a million Americans every year.
In the study, one dose of the anti-epilepsy drug, retigabine, preserved brain tissue in a mouse model of stroke and prevented the loss of balance control and motor coordination. Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio conducted the study, which was published Feb. 3 in The Journal of Neuroscience.
Balance and coordination test
Hours after a stroke, both treated mice and a control group of mice were placed on a balance beam to observe motor coordination. The untreated mice displayed a pronounced loss of coordination with slips and falls. Treated mice had no difficulty with balance, ambulation or turning around on the beam.
"You couldn't even tell they had a stroke," said senior author Mark S. Shapiro, Ph.D., professor of physiology at the UT Health Science Center San Antonio. "They ran across the balance beam like gymnasts."
Histological analysis of the brain tissue of treated mice showed significantly reduced damage to the tissue after the stroke, compared to untreated mice. The protective effects of the medication were observed in treated mice up to five days after the stroke, said Sonya Bierbower, Ph.D., postdoctoral fellow and lead author of the report.
Duration of effect
Future studies will assess how long brain function can be protected after a stroke, and whether injury-related seizures can be prevented. "We are also going to see if we can prevent strokes in high-risk animal models," Dr. Bierbower said.
Retigabine and similar agents open specific proteins called potassium ion channels, whose action stops the electrical activity of nerve cells in the brain. The San Antonio team studied ischemic stroke, in which oxygen and nutrients are suddenly cut off due to a clot in a blood vessel. This is the type of stroke most often seen in humans. "We thought if we could stop the neurons from firing, stopping their electrical activity, we could conserve their resources until the time their blood supply was restored," Dr. Shapiro said. "This proved to be the case."
Cells starved of oxygen and nutrients for six hours are compromised and the process of dying is nearly impossible to reverse. Moreover, when cells die, they release factors that trigger many types of responses including an inflammatory response, leading to more cell death in the areas around the blood clot.
tPA for clots
A drug called tissue plasminogen activator (tPA) treats stroke by dissolving clots to restore blood flow, but this has significant limitations. tPA causes severe thinning of the blood, so it is not an option for patients who have high blood pressure, a history of bleeding or weak blood vessels. tPA is most effective in the first hours after a stroke, but its later use may do more damage than good.
Directly affecting nerve cells
Potassium channel openers such as retigabine work on a completely different system. "They have nothing to do with thinning blood, but preserving cells by putting a brake on their electrical activity," Dr. Shapiro said.
"It's treating the first step in the sequence and stopping the more damaging secondary effects," Dr. Bierbower said. "These agents directly affect the nerve cells themselves."
FDA approved for epilepsy
Because retigabine is approved by the U.S. Food and Drug Administration under the American brand name Ezogabine as an anticonvulsant, physicians may use it off label in stroke patients. FDA approval for specifically this drug as stroke therapy will require a clinical trial to be conducted, and a team of neurologists and neurosurgeons at the Health Science Center is considering it, Dr. Shapiro said.
"As a leading cause of death and disability, stroke poses a major risk to our society," said David F. Jimenez, M.D., FACS, professor and chairman of the Department of Neurosurgery at the Health Science Center. "It is very exciting to see that our collaborative work with our colleagues in physiology could provide a superb way to ameliorate the harmful effects of stroke on our patients."


Saturday, July 1, 2017

Opioids Were Never Intended To Improve Function Just Relieve Pain


Today's post from clinicalpainadvisor.com (see link below) is an ever-so-subtle addition to the current media-inspired movement that claims all things 'opioid' are bad. It addresses opioids and neuropathic pain directly and comes to negative conclusions based on the study results that show that opioids produce little improvement in function in people who take them. However, opioids don't address the disease and are not meant to be 'cures'. Don't these people realise that opioids are never meant to improve function - they're meant to reduce pain and in that respect, they are very successful. Of course, reduced pain can enable people to function better but only because their pain is gone, not because the original illness has been addressed. Of course the media realise this full well! Inventing negative effects that were never claimed to be benefits of opioid use in the first place, is a sort of negative publicity that's used in politics all the time. The fact is that if you are taking opioids for neuropathic pain, you have tried everything else and nothing works, leaving you with opioids that generally do the job. Of course they have to be controlled and monitored and the patient has to take some responsibility to make sure that the potential for addiction is minimised but good doctors should be monitoring you to within an inch of your life to make sure you're not entering any sort of spiral. Opioids have been used for pain control since the dawn of time but like everything in this modern world, we always seem to need a sledgehammer to crack a nut!


How Effective Are Opioids in Neuropathic Pain? 
Steve Duffy January 26, 2016

Improved function may not necessarily follow opioid treatment.

A new study suggests that opioid prescriptions for patients with neuropathic pain, may not improve their physical function or disability. In fact, results from the study — conducted by the University of Alberta and published in Pain Medicine — indicate that opioid use could be harmful when it comes to physical recovery for patients with neuropathic pain.

"We studied patients with neuropathic pain from nerve injuries such as diabetic neuropathy and pinched nerves, and the ones who weren't prescribed any opioids had statistically lower disability and higher physical functioning scores," said Geoff Bostick, PhD, lead author of the study.

TRENDING ON CPA: ACA Supports Proposed Guideline for Prescribing Opioids to Patients With Chronic Pain

The study sample included 789 patients with neuropathic pain across Canada. Patients gave self-reported measures of physical function (pain disability index) and a medical outcomes study short form-12 physical function (PCSS-12), at the beginning of the study, then again at 6 months and 12 months after treatment began. Analysis of covariance models was created to examine the association between opioid therapy and both physical functioning outcomes with adjustment for confounding.

Results showed that patients prescribed opioid treatment did not report greater physical functioning or lower disability than patients who were not prescribed opioids — even after the results were adjusted for disease severity. The improvements in disability and physical functioning scores from baseline and 12 months for all groups were "modest and may not be clinically significant," authors reported.

They asserted that while opioids are a powerful painkiller, the results of the study testify that improved function does not necessarily follow opioid treatment.

In addition, they highlighted the association between opioid prescription and a patient's quality of life, considering that the treatment may not be aiding the patient's functionality. They call for further research to analyze this correlation.

For those who have chronic pain but are medically cleared for physical activity, a graded approach to recovery is suggested, according to Dr. Bostick. "I tell patients to walk until they are at 50% of their tolerance — walk and stop before the pain gets too bad. Each week, walking time is gradually increased. Over time, this tolerance will slowly increase and so will physical function."
Reference

Bostick G, Toth C, Carr E et al. Physical Functioning and Opioid use in Patients with Neuropathic Pain. Pain Med. 2015;16(7):1361-1368. doi:10.1111/pme.12702.
This article originally appeared on MPR.


http://www.clinicalpainadvisor.com/neuropathic-pain/how-effective-are-opioids-in-neuropathic-pain/article/467341/